Maze Therapeutics, Inc. Common Stock (MAZE) Stock Price

MAZEStock
$30.42+119.42%52W
Market Cap$1.69B
P/E77.66x
PEG Ratio
Div yield
Beta1.11

MAZE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-45.59%
Price vs S&P 500 (4W)3.12%
VGM Score68.58
P/E Ratio (Annual)77.66x

MAZE Earnings Surprise History

Q2 25-0.77est. -1.16
Q3 25-0.66est. -0.69
Q4 25-0.65est. -0.69
Q2 26-0.76est. -0.70

MAZE Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.33
4.33
4.33

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
MAZEMaze Therapeutics, Inc. Common Stock
B$30.42
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Maze Therapeutics, Inc. Common Stock

Maze Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for chronic kidney disease, cardiovascular disease, and obesity using its proprietary Compass platform. The platform identifies disease-causing genetic variants and links them to underlying biological pathways, enabling targeted therapeutic development. The company is advancing two lead programs—MZE829 and MZE782—both designed to treat chronic kidney disease.